ELI LILLY AND COMPANY (NYSE:LLY) Files An 8-K Completion of Acquisition or Disposition of Assets
Item 2.01 Completion of Acquisition or Disposition of Assets.
On March 11, 2019, Eli Lilly and Company (“Lilly”) completed the previously announced split-off of Elanco Animal Health Incorporated (“Elanco”), to which Lilly accepted 65,000,775 shares of Lilly common stock from its shareholders in exchange for the 293,290,000 shares of Elanco common stock that it owned.
Item 9.01 Financial Statements and Exhibits.
(b) Pro Forma Financial Information.
The following unaudited pro forma financial information of Lilly is furnished as Exhibit 99.1 of this Current Report on Form 8-K and is incorporated herein by reference:
|
Unaudited pro forma condensed consolidated balance sheet at December 31, 2018. |
|
Unaudited pro forma condensed consolidated statements of operations for each of the years ended December 31, 2018, 2017 and 2016. |
|
Notes to the unaudited pro forma condensed consolidated financial statements. |
(d) Exhibits.
|
Exhibit Number |
Description of Exhibit |
|
99.1 |
Eli Lilly and Company Unaudited Pro Forma Condensed Consolidated Financial Statements |
EXHIBIT INDEX
LILLY ELI & CO Exhibit
EX-99.1 2 exhibit991-elilillyandcomp.htm EXHIBIT 99.1 Exhibit UNAUDITED PRO FORMA CONDENSED CONSOLIDATED FINANCIAL STATEMENTSELI LILLY AND COMPANY AND SUBSIDIARIESOn March 11,…
To view the full exhibit click here
About ELI LILLY AND COMPANY (NYSE:LLY)
Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists. Its animal health business segment operates through the Company’s Elanco division, which develops, manufactures and markets products for both food animals and companion animals. The Company’s human pharmaceutical products include endocrinology products, such as Humalog and Humalog Mix 75/25; neuroscience products, such as Cymbalta and Zyprexa; oncology products, such as Alimta and Cyramza, and cardiovascular products, such as Cialis and ReoPro. The Company’s animal health products segment includes products for food animals, such as Rumensin and Posilac; products for companion animals, such as Onsior and Osurnia, and Novartis Animal Health (Novartis AH) products.
